EP
AKBA icon

Eudaimonia Partners’s Akebia Therapeutics AKBA Stock Holding History

Eudaimonia Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$47.5K Sell
25,945
-799
-3% -$1.28K 0.01% 255
2023
Q4 		$33.2K Sell
26,744
-400
-1% -$408 0.01% 249
2023
Q3 		$30.9K Hold
27,144
– – 0.01% 327
2023
Q2 		$24.8K Buy
27,144
+15,000
+124% +$14.5K 0.01% 345
2023
Q1 		$6.81K Buy
+12,144
New +$9.28K ﹤0.01% 349
2022
Q4 		– Sell
-27,144
Closed -$9K – 344
2022
Q3 		$9K Hold
27,144
– – ﹤0.01% 339
2022
Q2 		$10K Hold
27,144
– – ﹤0.01% 387
2022
Q1 		$19K Buy
+27,144
New +$58.1K ﹤0.01% 403

Other funds holding AKBA

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Eudaimonia Partners's AKBA Position: Q1 2024 in Review

Eudaimonia Partners reduced its Akebia Therapeutics (AKBA) stake by 3% in Q1 2024, selling an estimated $1.28K and leaving 25,945 shares worth $47.5K. The position accounts for 0.01% of the portfolio, ranked #255.

Eudaimonia Partners first reported a position in AKBA in Q1 2022 and has held it in 8 quarters since. 114 funds tracked by Wall St. Rank hold AKBA as of Q1 2024.

  • Eudaimonia Partners held 25,945 shares of Akebia Therapeutics worth $47.5K as of Q1 2024.
  • Eudaimonia Partners sold 799 Akebia Therapeutics shares in Q1 2024, an estimated $1.28K.
  • Akebia Therapeutics made up 0.01% of Eudaimonia Partners's portfolio in Q1 2024, its #255 holding.
  • Eudaimonia Partners first reported a position in Akebia Therapeutics in Q1 2022 and has held it in 8 quarters since.
  • 114 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2024.

Based on Eudaimonia Partners's 13F filing for Q1 2024, filed 25 Apr 2024.